Apogenix Raises EUR 7.5 Million to Further Advance APG101 to Treat Glioblastoma and other Tumors
0
Apogenix /
Apogenix Raises EUR 7.5 Million to Further Advance APG101 to Treat Glioblastoma
and other Tumors
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* All existing investors participated in this financing round
* Clinical proof-of-concept data with APG101 expected in Q1/2012
Heidelberg, January 5, 2012 - The biopharmaceutical company Apogenix GmbH today
announced the successful completion of a EUR 7.5 million financing round led by
dievini Hopp BioTech holding GmbH & Co. KG (dievini). Other investors include
the German Cancer Research Center (DKFZ), the founders and the executive
management team of Apogenix. These funds will enable Apogenix to further advance
the phase II clinical trial of APG101 to treat Glioblastoma Multiforme (GBM) and
other cancer indications.
APG101 is a first-in-class, fully human protein that provides an innovative
therapeutic approach to treating solid tumors such as GBM. APG101 is the most
advanced inhibitor of the CD95 ligand (CD95L) in clinical development. In
September 2011, Apogenix announced the completion of patient recruitment of its
phase II clinical trial in GBM. Final results of this trial are expected in the
first quarter of 2012.
"APG101 has great potential to treat Glioblastoma patients, a disease with very
few treatment options. With the sustained support of our existing investors, we
can continue to exploit the therapeutic potential of this innovative compound",
said Dr Thomas Höger, CEO/CFO of Apogenix. "Based on the phase II GBM data, we
will approach potential partners to explore their interest in the therapeutic
and economic potential of APG101."
Dr Friedrich von Bohlen, Chairman of the Board of Apogenix and Managing Director
of dievini commented: "We are very pleased with the progress of the APG101
program that is expected soon to show clinical proof-of-concept. Based on
existing data and findings, everyone at Apogenix is excited about the
therapeutic and commercial potential of this novel compound and treatment option
for the most common and aggressive type of primary brain tumor as well as other
solid tumors."
About Apogenix
Apogenix, a spin-out from the German Cancer Research Center (DKFZ), is
developing novel protein therapeutics for the treatment of cancer and
inflammatory diseases based either on the targeted modulation of apoptosis
(programmed cell death) or on blocking the growth of tumor cells. The company´s
lead product candidate APG101 is being developed for the treatment of
Glioblastoma Multiforme (GBM), the most common and aggressive type of primary
brain tumor. Since its inception in 2005, the company has raised more than EUR 50
million with dievini Hopp BioTech Holding GmbH & Co. KG as main investor, and
has been awarded public grants totaling over EUR 8 million. Apogenix is based in
Heidelberg, Germany.
About APG101
The company´s lead product candidate, APG101, a first-in-class, fully human,
soluble fusion protein combining the extracellular domain of the CD95 receptor
and the Fc portion of IgG, successfully completed a phase I study in 2009. In
December 2009, Apogenix started a controlled phase II trial with APG101 for the
treatment of Glioblastoma Multiforme. The patient recruitment for this study was
completed in September 2011. Apogenix was granted orphan drug designation for
APG101 in 2009 for the treatment of GBM in Europe and in the US.
Contact
Dr Thomas Höger Raimund Gabriel
CEO/CFO MC Services AG
Apogenix GmbH Phone: +49 (89) 210 228 30
Phone: +49 (6221) 5 86 08-0 Email: raimund.gabriel@mc-services.eu
Email: contact@apogenix.com
www.apogenix.com
--- End of Message ---
Apogenix
Apogenix GmbH Heidelberg Germany
Press release (PDF):
http://hugin.info/146079/R/1575169/490548.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Apogenix via Thomson Reuters ONE
[HUG#1575169]
